Senicapoc
- Generic Name
- Senicapoc
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15F2NO
- CAS Number
- 289656-45-7
- Unique Ingredient Identifier
- TS6G201A6Q
- Background
Senicapoc (ICA-17043) is a novel Gardos channel blocker. It is being investigated for the treatment of sickle cell disease.
- Indication
Investigated for use/treatment in anemia (sickle cell) and asthma.
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
- Conditions
- Pulmonary Fibrosis, Interstitial Lung DiseaseIdiopathic Pulmonary Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT06714123
- Locations
- π©π°
Aarhus University Hospital, Aarhus N, Denmark
π©π°Gentofte Hospital, Hellerup, Denmark
π©π°Odense University Hospital, Odense C, Denmark
Senicapoc in Alzheimer's Disease
- Conditions
- Mild Cognitive ImpairmentAlzheimer Disease
- Interventions
- Other: Placebo Tablet
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 55
- Registration Number
- NCT04804241
- Locations
- πΊπΈ
University of California, Davis Alzheimer's Disease Center, Sacramento, California, United States
πΊπΈUC Davis Alzheimer's Disease Center East Bay, Walnut Creek, California, United States
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 46
- Registration Number
- NCT04594668
- Locations
- π©π°
Odense University Hospital, Odense, Denmark
π©π°Hvidovre Hospital, Hvidovre, Denmark
π©π°Aalborg University Hospital, Aalborg, Denmark
Senicapoc and Dehydrated Stomatocytosis
- Conditions
- Dehydrated Hereditary Stomatocytosis
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT04372498
- Locations
- πΊπΈ
Boston Children's Hospital, Boston, Massachusetts, United States
Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Icagen
- Target Recruit Count
- 69
- Registration Number
- NCT00861185
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Icagen
- Target Recruit Count
- 34
- Registration Number
- NCT00861211
- Locations
- π¬π§
Guy's Drug Research Unit, London, UK, United Kingdom
π¬π§Medicines Evaluation Unit, Manchester, UK, United Kingdom
A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
- Conditions
- Sickle Cell DiseaseSickle Cell Anemia
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Icagen
- Target Recruit Count
- 51
- Registration Number
- NCT00294541
- Locations
- πΊπΈ
East Carolina University School of Medicine, Greenville, North Carolina, United States
πΊπΈNewark Beth Israel Medical Center, Newark, New Jersey, United States
πΊπΈBrigham and Women's Hospital, Boston, Massachusetts, United States
A Stratified Sickle Event Randomized Trial (ASSERT)
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Icagen
- Target Recruit Count
- 297
- Registration Number
- NCT00102791
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.